


ThyGenNEXT with Reflex to ThyraMIR

Order Name: **ThyGenNEXT Rflx**  
Test Number: **6907017**  
Revision Date: **10/01/2022**

TEST NAME	METHODOLOGY	LOINC CODE
ThyGeNEXT	<a href="#">MicroRNA (miRNA) Profiling</a>	n/a
ThyraMIR	<a href="#">MicroRNA (miRNA) Profiling</a>	n/a
Nodule	<a href="#">Specimen Information</a>	n/a
Cytopathology	<a href="#">Patient Information</a>	n/a
Risk Assessment	<a href="#">Calculation</a>	n/a
ThyGen Interpretation	<a href="#">Interpretive information.</a>	n/a

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	1 Vial	Fine Needle Aspirate	RNARetain vial	Room Temperature
Instructions	ThyGenNext testing is performed following an indeterminate FNA Cytology evaluation. Contact Labcorp Oklahoma, Inc. for FNA collection kit with special collection vial, instructions and requisition <b>Specimen collection:</b> Fine needle aspiration of thyroid nodule in RNARetain vial (small amount, 3rd or 4th pass) <b>Specimen preparation:</b> Send vial with cytology preparations at room temperature <b>Stability:</b> Ambient - 6 weeks  <b>Performing Lab Information and Requisition</b>			

GENERAL INFORMATION	
Testing Schedule	Varies
Expected TAT	7-14 days after pathology interpretation
Clinical Use	ThyGeNEXT® with Reflex to ThyraMIR® better discriminates benign from malignant nodules and provides risk assessment. TERT and BRAF mutations are included in ThyGeNEXT® . If mutations in ThyGeNEXT® are negative or not fully indicative of malignancy, the ThyraMIR® testing will be performed as reflex.
Notes	<b>INTERFACE ORDERING:</b> ThyGenNEXT Rflx Order should be placed in addition to the electronic Cytology order. <b>RESULT/REPORT CHANGE:</b> ThyGenNEXT & ThyraMIR were previously reported as an addendum to the FNA Cytology report. They will now be reported from the General Laboratory section.
CPT Code(s)	0245U + 0018U if reflexed ThyraMIR Molecular testing is reflexed if mutations in ThyGeNEXT are negative or not fully indicative of malignancy.
Service Provided By	 <b>labcorp</b> Oklahoma, Inc.